Exploring the human gut microbiota enzymes involved in the complex carbohydrate degradation

La présence de sucres complexes constitue une source nutritive importante pour le microbiote qui assure leur dégradation via des CAZymes. Dans le cadre de cette thèse, nous avons construit in silico un modèle de type minimicrobiome contenant 177 génomes représentatifs des communautés bactériennes dans un microbiote intestinal conventionnel. L’analyse du contenu de ce minimicrobiome nous a permis d’estimer leur abondance et leur diversité. De plus, la comparaison du contenu CAZymes par groupe bactérien de type « phylum » a révélé une variabilité inter-phylum, notamment une diversité de familles CAZymes et une abondance en gènes bien plus élevées chez les Bacteroidetes. Dans un deuxième temps, nous avons développé une puce à ADN sur laquelle nous avons greffé des sondes non redondantes ciblant plus de 6500 gènes codant des CAZymes. Nous avons ensuite testé la "puce CAZyme" par hybridation d’ADN bactérien extrait d’échantillons de selles. Nos résultats suggèrent que cette méthode serait plus sensible dans la détection de CAZymes provenant de bactéries rares par rapport à la métagénomique. Ainsi, il est intéressant de noter qu’en utilisant la puce CAZyme, nous avons pu détecter un gène codant pour une famille GH6, alors que les études métagénomiques n’ont jamais réussi à détecter ce gène dans le microbiome intestinal humain et animal. Enfin, l’examen de huit échantillons de selles a permis l’identification d’un noyau CAZome contenant 46 familles de GHs et PLs, ce qui suggérerait que le microbiote intestinal est caractérisé par une stabilité fonctionnelle en dépit de variations taxonomiques importantes entre les individus testés et indépendamment de leur état de santé.The bacterial communities that inhabit our gut ensure their growth and survival by extracting their carbon source from the food that transits through the intestines. The complex carbohydrates included in the human diet are almost exclusively degraded by the gut microbiota using CAZymes. We built a minimicrobiome model using 177 genomes associated to gut microbiota. The CAZyme content analysis revealed their huge diversity and abundance in our minimicrobiome model. At the phylum level, the Bacteroidetes genomes showed the greatest CAZyme diversity and abundance. Interestingly, as most of CAZymes found in Bacteroidetes genomes contain a signal peptide allowing their secretion in the intestinal lumen and/or in periplasmic space, members of this phylum are suggested to be the primary degraders of complex carbohydrates. Further, we developed a microarray containing probes to target more than 6,500 CAZyme genes. We then validated the CAZyme microarray by the hybridization of bacterial DNA extracted from the stool samples of individuals. Our results suggest that a microarray-based study can detect genes from low-abundance bacteria better than metagenomic-based studies. A striking example was the detection of gene encoding a GH6-family in all subjects examined, whereas metagenomic studies have consistently failed to detect this gene in both human and animal gut microbiomes. In addition, an examination of eight stool samples allowed the identification of a corresponding core CAZome containing 46 CAZymes families that suggests a functional stability of the gut microbiota despite large taxonomical variations between individuals and independently of health state

Le microbiote intestinal et la digestion des polysaccharides

Le microbiote intestinal distal correspond à l’ensemble des micro-organismes, essentiellement des bactéries, qui résident habituellement dans le côlon. Cette population microbienne est caractérisée par une grande diversité taxonomique ; on estime à environ un millier le nombre d’espèces bactériennes distinctes pour un seul individu. L’étude de ce système microbien a brutalement accéléré ces dernières années grâce à l’avènement de techniques dites métagénomiques, qui s’affranchissent de la culture bactérienne et reposent sur le séquençage de l’ADN. En quelques années, le microbiote intestinal a fait l’objet de nombreuses études, aux résultats souvent contradictoires, qui tentent de corréler les variations de la population bactérienne à diverses pathologies. Cet article fait le point sur une des fonctions essentielles du microbiote intestinal : la digestion de l’immense diversité des polysaccharides de notre alimentation, que les enzymes de l’hôte ne peuvent digérer

A metagenomics investigation of carbohydrate-active enzymes along the goat and camel intestinal tract

International audienceStudies of the digestive microbiota of ruminant animals most often focus on the bacterial diversity in the rumen or the feces of the animals, but little is known about the diversity and functions of their distal intestine. Here, the bacterial microbiota of the distal intestinal tract of two goats and two camels was investigated by metagenomics techniques. The bacterial taxonomic diversity and carbohydrate-active enzyme profile were estimated for samples taken from the small intestine, the large intestine, and the rectum of each animal. The bacterial diversity and abundance in the small intestine were lower than in the rectal and large intestinal samples. Analysis of the carbohydrate-active enzyme profiles at each site revealed a comparatively low abundance of enzymes targeting xylan and cellulose in all animals examined, similar to what has been reported earlier for sheep and therefore suggesting that plant cell wall digestion probably takes place elsewhere, such as in the rumen

Development and validation of a microarray for the investigation of the CAZymes encoded by the human gut microbiome.

Distal gut bacteria play a pivotal role in the digestion of dietary polysaccharides by producing a large number of carbohydrate-active enzymes (CAZymes) that the host otherwise does not produce. We report here the design of a custom microarray that we used to spot non-redundant DNA probes for more than 6,500 genes encoding glycoside hydrolases and lyases selected from 174 reference genomes from distal gut bacteria. The custom microarray was tested and validated by the hybridization of bacterial DNA extracted from the stool samples of lean, obese and anorexic individuals. Our results suggest that a microarray-based study can detect genes from low-abundance bacteria better than metagenomic-based studies. A striking example was the finding that a gene encoding a GH6-family cellulase was present in all subjects examined, whereas metagenomic studies have consistently failed to detect this gene in both human and animal gut microbiomes. In addition, an examination of eight stool samples allowed the identification of a corresponding CAZome core containing 46 families of glycoside hydrolases and polysaccharide lyases, which suggests the functional stability of the gut microbiota despite large taxonomical variations between individuals

Comparative genomics analysis of Lactobacillus species associated with weight gain or weight protection

International audienceBACKGROUND: Some Lactobacillus species are associated with obesity and weight gain while others are associated with weight loss. Lactobacillus spp. and bifidobacteria represent a major bacterial population of the small intestine where lipids and simple carbohydrates are absorbed, particularly in the duodenum and jejunum. The objective of this study was to identify Lactobacillus spp. proteins involved in carbohydrate and lipid metabolism associated with weight modifications. METHODS: We examined a total of 13 complete genomes belonging to seven different Lactobacillus spp. previously associated with weight gain or weight protection. We combined the data obtained from the Rapid Annotation using Subsystem Technology, Batch CD-Search and Gene Ontology to classify gene function in each genome. RESULTS: We observed major differences between the two groups of genomes. Weight gain-associated Lactobacillus spp. appear to lack enzymes involved in the catabolism of fructose, defense against oxidative stress and the synthesis of dextrin, L-rhamnose and acetate. Weight protection-associated Lactobacillus spp. encoded a significant gene amount of glucose permease. Regarding lipid metabolism, thiolases were only encoded in the genome of weight gain-associated Lactobacillus spp. In addition, we identified 18 different types of bacteriocins in the studied genomes, and weight gain-associated Lactobacillus spp. encoded more bacteriocins than weight protection-associated Lactobacillus spp. CONCLUSIONS: The results of this study revealed that weight protection-associated Lactobacillus spp. have developed defense mechanisms for enhanced glycolysis and defense against oxidative stress. Weight gain-associated Lactobacillus spp. possess a limited ability to breakdown fructose or glucose and might reduce ileal brake effects

A Metagenomics Investigation of Carbohydrate-Active Enzymes along the Gastrointestinal Tract of Saudi Sheep

The digestive microbiota of humans and of a wide range of animals has recently become amenable to in-depth studies due to the emergence of DNA-based metagenomic techniques that do not require cultivation of gut microbes. These techniques are now commonly used to explore the feces of humans and animals under the assumption that such samples are faithful proxies for the intestinal microbiota. Sheep (Ovis aries) are ruminant animals particularly adapted to life in arid regions and in particular Najdi, Noaimi (Awassi), and Harrei (Harri) breeds that are raised in Saudi Arabia for milk and/or meat production. Here we report a metagenomics investigation of the distal digestive tract of one animal from each breed that (i) examines the microbiota at three intestinal subsites (small intestine, mid-colon, and rectum), (0 performs an in-depth analysis of the carbohydrate-active enzymes genes encoded by the microbiota at the three subsites, and (iii) compares the microbiota and carbohydrate-active enzyme profile at the three subsites across the different breeds. For all animals we found that the small intestine is characterized by a lower taxonomic diversity than that of the large intestine and of the rectal samples. Mirroring this observation, we also find that the spectrum of encoded carbohydrate-active enzymes of the mid-colon and rectal sites is much richer than that of the small intestine. However, the number of encoded cellulases and xylanases in the various intestinal subsites was found to be surprisingly low, indicating that the bulk of the fiber digestion is performed upstream in the rumen, and that the carbon source for the intestinal flora is probably constituted of the rumen fungi and bacteria that pass in the intestines. In consequence we argue that ruminant feces, which are often analyzed for the search of microbial genes involved in plant cell wall degradation, are probably a poor proxy for the lignocellulolytic potential of the host

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis

International audienceBackground: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an important heterogeneity, reflected by different clinical outcomes and chemoresistance. During carcinogenesis, tumor cells display aberrant glycosylated structures, synthetized by deregulated glycosyltransferases, supporting the tumor progression. In this study, we aimed to determine whether PDAC could be stratified through their glycosyltransferase expression profiles better than the current binary classification (basal-like and classical) in order to improve detection of patients with poor prognosis.Methods: Bioinformatic analysis of 169 glycosyltransferase RNA sequencing data were performed for 74 patient-derived xenografts (PDX) of resected and unresectable tumors. The Australian cohort of International Cancer Genome Consortium and the microarray dataset from Puleo patient's cohort were used as independent validation datasets.Findings: New PDAC stratification based on glycosyltransferase expression profile allowed to distinguish different groups of patients with distinct clinical outcome (p-value = 0.007). A combination of 19 glycosyltransferases differentially expressed in PDX defined a glyco-signature, whose prognostic value was validated on datasets including resected whole tumor tissues. The glyco-signature was able to discriminate three clusters of PDAC patients on the validation cohorts, two clusters displaying a short overall survival compared to one cluster having a better prognosis. Both poor prognostic clusters having different glyco-profiles in Puleo patient's cohort were correlated with stroma activated or desmoplastic subtypes corresponding to distinct microenvironment features (p-value < 0.0001). Besides, differential expression and enrichment analyses revealed deregulated functional pathways specific to different clusters.Interpretation: This study identifies a glyco-signature relevant for a prognostic use, potentially applicable to resected and unresectable PDAC. Furthermore, it provides new potential therapeutic targets.Funding: This work was supported by INCa (Grants number 2018-078 and 2018-079), Fondation ARC (Grant number ARCPJA32020070002326), Cancéropôle PACA, DGOS (labelization SIRIC, Grant number 6038), Amidex Foundation and Ligue Nationale Contre le Cancer and by institutional fundings from INSERM and the Aix-Marseille Université

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

International audienceBackground: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease.Methods: In this study, we perform the metabolomics profiling of 77 PDAC patient-derived tumor xenografts (PDTX) to investigate the relationship of metabolic profiles with overall survival (OS) in PDAC patients, tumor phenotypes and resistance to five anticancer drugs (gemcitabine, oxaliplatin, docetaxel, SN-38 and 5-Fluorouracil).Findings: We identified a metabolic signature that was able to predict the clinical outcome of PDAC patients (p < 0.001, HR=2.68 [95% CI: 1.5-4.9]). The correlation analysis showed that this metabolomic signature was significantly correlated with the PDAC molecular gradient (PAMG) (R = 0.44 and p < 0.001) indicating significant association to the transcriptomic phenotypes of tumors. Resistance score established, based on growth rate inhibition metrics using 35 PDTX-derived primary cells, allowed to identify several metabolites related to drug resistance which was globally accompanied by accumulation of several diacy-phospholipids and decrease in lysophospholipids. Interestingly, targeting glycerophospholipid synthesis improved sensitivity to the three tested cytotoxic drugs indicating that interfering with metabolism could be a promising therapeutic strategy to overcome the challenging resistance of PDAC.Interpretation: In conclusion, this study shows that the metabolomic profile of pancreatic PDTX models is strongly associated to clinical outcome, transcriptomic phenotypes and drug resistance. We also showed that targeting the lipidomic profile could be used in combinatory therapies against chemoresistance in PDAC

BLAST results of sequenced PCR products against NCBI <i>nr</i> database.

<p>BLAST results of sequenced PCR products against NCBI <i>nr</i> database.</p

Comparison of detected CAZyme genes between and within samples.

<p>The numbers of unique and shared CAZyme genes between samples are represented as a Venn diagram. The phylum distribution of the core CAZyme genes of each group are shown in different colors (blue, Firmicutes; red, Bacteroidetes; yellow, Actinobacteria; purple, Proteobacteria; olive green, Lentisphaerae; brown, Verrucomicrobia). The CAZyme family composition of the cores is shown in rainbow colors.</p